HALO haven’t been truthful with shareholders (until after the PEG disaster) about the halving of royalty rates after the Enhanze patents expire in just a few years time. It’s clear that big pharma is well aware that the longer they delay the cheaper the royalties payable to HALO will be (other than on co-formulations). I thought it was just Baxter and then Roche (in the US) who were taking advantage of the situation but I think that they’re all at it. I think HALO’s future lies in the hands of big pharma, who in fact only have their own best interests at heart - not HALO’s. I am hugely disillusioned by HALO being so economical with the truth for so long. In my opinion nobody is going to be buying HALO at anything like the current inflated price. It’s all very clever to borrow huge amounts of money to buy-back your own shares - but in reality to was just a smart device to enable RJK to exit quickly. I’ve done the same.
News 
Market Data 
Discover 
